Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
Title
Type
[
Year
]
Filters:
Author
is
Gil, Lidia
[Clear All Filters]
2023
Dytfeld D
,
Wróbel T
,
Jamroziak K
,
Kubicki T
,
Robak P
,
Walter-Croneck A
,
Czyż J
,
Tyczyńska A
,
Druzd-Sitek A
,
Giannopoulos K
, et al.
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Lancet Oncol. 2023.
PubMed
Google Scholar
Styczyński J
,
Tridello G
,
Koster L
,
Knelange N
,
Wendel L
,
van Biezen A
,
van der Werf S
,
Mikulska M
,
Gil L
,
Cordonnier C
, et al.
Decrease of lethal infectious complications in the context of causes of death (COD) after hematopoietic cell transplantation: COD-2 and COD-1 study of the Infectious Diseases Working Party EBMT.
Bone Marrow Transplant. 2023.
PubMed
Google Scholar
Kubicki T
,
Dytfeld D
,
Wróbel T
,
Jamroziak K
,
Robak P
,
Czyż J
,
Tyczyńska A
,
Druzd-Sitek A
,
Giannopoulos K
,
Szczepaniak T
, et al.
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis
. Br J Haematol. 2023.
PubMed
Google Scholar
2020
Gołos A
,
Gil L
,
Puła B
,
Boguradzki P
,
Hałaburda K
,
Sawicki W
,
Sobczyk-Kruszelnicka M
,
Helbig G
,
Dybko J
,
Jurczyszyn A
, et al.
Allogeneic hematopoietic cell transplantation for multiple myeloma: A retrospective analysis of the Polish Myeloma Group.
Adv Med Sci. 2020;65(2):429-436.
PubMed
Google Scholar
2019
Czyzewski K
,
Gałązka P
,
Frączkiewicz J
,
Salamonowicz M
,
Szmydki-Baran A
,
Zając-Spychała O
,
Gryniewicz-Kwiatkowska O
,
Zalas-Więcek P
,
Chełmecka-Wiktorczyk L
,
Irga-Jaworska N
, et al.
Epidemiology and outcome of invasive fungal disease in children after hematopoietic cell transplantation or treated for malignancy: impact of national program of antifungal prophylaxis.
Mycoses. 2019.
PubMed
Google Scholar
2012
Gil L
,
Styczyński J
,
Komarnicki M
.
Strategy of pre-emptive management of Epstein-Barr virus post-transplant lymphoproliferative disorder after stem cell transplantation: results of European transplant centers survey.
Contemp Oncol (Pozn). 2012;16(4):338-340.
PubMed
Google Scholar